Metabolic diseases affect various organs including the brain. Accumulation or depletion of substrates frequently leads to brain injury and dysfunction. Deficiency of aminopeptidase P1, a cytosolic proline-specific peptidase encoded by the Xpnpep1 gene, causes an inborn error of metabolism (IEM) characterized by peptiduria in humans. We previously reported that knockout of aminopeptidase P1 in mice causes neurodevelopmental disorders and peptiduria. However, little is known about the pathophysiological role of aminopeptidase P1 in the brain. Here, we show that loss of aminopeptidase P1 causes behavioral and neurological deficits in mice. Mice deficient in aminopeptidase P1 (Xpnpep1 −/− ) display abnormally enhanced locomotor activities in both the home cage and open-field box. The aminopeptidase P1 deficiency in mice also resulted in severe impairments in novel-object recognition, the Morris water maze task, and contextual, but not cued, fear memory. These behavioral dysfunctions were accompanied by epileptiform electroencephalogram activity and neurodegeneration in the hippocampus. However, mice with a heterozygous mutation for aminopeptidase P1 (Xpnpep1 +/− ) exhibited normal behaviors and brain structure. These results suggest that loss of aminopeptidase P1 leads to behavioral, cognitive and neurological deficits. This study may provide insight into new pathogenic mechanisms for brain dysfunction related to IEMs.
Undisturbed metabolism is important for normal brain function and development. The accumulation of toxic metabolites or deficiency of necessary substances resulting from a defective metabolic process frequently leads to brain dysfunction and abnormalities. Inborn errors of metabolism (IEMs), also known as inheritable metabolic diseases, are common causes of brain injury and dysfunction (Gropman 2012; Kahler & Fahey 2003; Pierre 2013; Sedel et al. 2007; Wolf et al. 2005) . Most IEMs are caused by mutations in genes coding for enzymes, and hundreds of IEMs have been discovered to date. However, IEMs are extremely diverse, and individual IEMs are rare (Applegarth et al. 2000; Raghuveer et al. 2006; Sanderson et al. 2006) , which hinders the understanding of the individual disease and the pathophysiological roles of the responsible gene in the brain. Animal models for rare diseases therefore provide valuable insights into the neurobiology of the diseases. Investigations of rare diseases are important because they provide not only greater equality of treatment access for patients with rare diseases but also a further understanding of extreme pathology and normal physiology (Pariser & Gahl 2014; Schieppati et al. 2008) .
A deficiency in aminopeptidase P1, also known as cytosolic aminopeptidase P and X-prolyl aminopeptidase 1, is known to cause an IEM characterized by peptiduria in humans (Blau et al. 1988) . Massive urinary excretion of undigested peptides containing a penultimate proline has been observed in brothers with aminopeptidase P1 deficiency. Aminopeptidase P1 belongs to a family of aminopeptidase Ps (aminopeptidases P1-3 encoded by the Xpnpep1-3 genes) that cleave the first residue of a peptide containing a proline residue at the second position (Cottrell et al. 2000; Ersahin et al. 2005) . Because proline-adjacent bonds in peptides are highly resistant to non-specific proteolytic degradation, cleavage of the N-terminal X-Pro motifs (where X represents any amino acid) in peptides is thought to be mediated solely by aminopeptidase Ps in mammals (Vanhoof et al. 1995) . Although the three aminopeptidase P isoforms are ubiquitously expressed in mammalian tissues, aminopeptidase P1 is the predominant isoform in the brain (Lein et al. 2007 ). Importantly, a human patient found to be deficient in aminopeptidase P1 activity exhibited microcephaly and epileptic seizures (Blau et al. 1988) , suggesting that accumulation of undigested imino-oligo peptides due to a lack of aminopeptidase P1 activity may affect normal brain development and function. However, the cognitive and behavioral functions of the patient are unknown.
We previously reported that knockout of Xpnpep1 (Xpnpep1 −/− ) in mice recapitulates the peptiduria of human aminopeptidase P1 deficiency (Yoon et al. 2012) . Mice with disrupted aminopeptidase P1 also exhibit a neurological disorder, microcephaly, which was observed in one of the aminopeptidase P1-deficient human subjects. The murine aminopeptidase P1 is 96% identical at the amino acid level to the human aminopeptidase P1 (Cottrell et al. 2000) .
In this study, by analyzing Xpnpep1 −/− mice, we investigated the behavioral and neurological consequences of aminopeptidase P1 deficiency in detail. We show that the metabolic dysfunction caused by the loss of aminopeptidase P1 leads to behavioral hyperactivity, epileptic EEG (electroencephalogram) discharges, and severely impaired hippocampus-dependent learning and memory in mice. Employing histological and biochemical approaches, we also show that the lack of the aminopeptidase P1 activity causes neurodegeneration in the CA3 region of the hippocampus. Thus, our study provides direct evidence that aminopeptidase P1 is important for normal brain function and development.
Materials and methods

Animals
The generation and genotyping of Xpnpep1 knockout mice has been previously described (Yoon et al. 2012) . Mice were backcrossed to C57BL/6J and 129S4/SvJae mice for 8-16 generations before use. All analyses were performed using littermates of both genotypes generated by the intercrosses between C57BL/6J and 129S4/SvJae heterozygous parents. Animals were housed 4-5 per cage in a specific pathogen-free facility. Animals were maintained in a climate-controlled room with free access to food and water in 12 h light/dark cycles with the light on at 7:00. Animal maintenance and all animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University.
Histochemistry
For the immunohistochemical staining, mice were deeply anesthetized with diethyl ether and transcardially perfused with heparinized (10 U/ml) phosphate-buffered saline (PBS), followed by perfusion with a fixative containing 4% (w/v) paraformaldehyde in PBS. Mouse brains were removed, post-fixed for 48 h at 4 ∘ C and cut into 60-μm coronal sections using a vibratome (VT1200S, Leica, Wetzlar, Germany). The sections were post-fixed in the same fixative for 1 h, permeabilized with 0.3% (v/v) Triton X-100 in PBS, incubated in blocking buffer (5% normal goat serum, 5% horse serum, 5% donkey serum and 0.5% BSA in PBS) for 2 h, incubated overnight at 4 ∘ C with primary antibodies, and then incubated with Cy3-or FITC-conjugated secondary antibodies for 2 h. After each step, the sections were rinsed three times for 10 min with PBS. In some immunohistochemical staining protocols, the sections were trypsinized for 30 min at 37 ∘ C prior to incubation in blocking buffer. Images were acquired using a confocal laser scanning microscope (LSM510, Zeiss, Oberkochen, Germany) or a fluorescence microscope (BX51WI, Olympus, Tokyo, Japan) equipped with a cooled charge-coupled device camera (DP70, Olympus, Japan).
For the hematoxylin and eosin (HE) staining, fixed mouse brains were oriented in the coronal plane and embedded in paraffin using an embedding module (Shandon Histocentre 3, Thermo Fisher Scientific, Waltham, MA, USA). Paraffin blocks were dissected into 4-μm sections using a rotary microtome (RM2145, Leica) and mounted onto glass slides. The slices were deparaffinized by successive immersion in xylene (three times for 10 min), 100% ethanol (twice for 1 min), 95% ethanol (twice) and running tap water. After dehydration, the deparaffinized sections were stained with hematoxylin (Merck, Darmstadt, Germany) and eosin (Sigma-Aldrich, St. Louis, MO, USA). The stained sections were rinsed with 95% ethanol, 100% ethanol and xylene. Images were acquired using a light microscope (BX51, Olympus) with a digital imaging system (DFC280, Leica).
Electron microscopy
Mice were deeply anesthetized with sodium pentobarbital (80 mg/kg, i.p.) and transcardially perfused with 10 ml of heparinized normal saline, followed by 50 ml of a freshly prepared fixative containing 2.5% glutaraldehyde and 1% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4). The hippocampus was removed from the whole brain, post-fixed in the same fixative for 2 h and stored in PB (0.1 M, pH 7.4) overnight at 4 ∘ C. Sections were cut transversely on a vibratome to 60 μm. The sections were osmicated with 1% osmium tetroxide (in 0.1 M PB) for 1 h, dehydrated in a graded alcohol series, flat-embedded in Durcupan ACM (Sigma-Aldrich), and cured for 48 h at 60 ∘ C. Small pieces containing the hippocampal CA3 region were cut out of the wafers and glued onto a plastic block using cyanoacrylate. Ultrathin sections were cut and mounted onto Formvar-coated single-slot grids. The sections were stained with uranyl acetate and lead citrate and examined with an electron microscope (Hitachi H-7500, Hitachi, Tokyo, Japan) at an 80-kV accelerating voltage. Digital images were captured using the GATAN DigitalMicrograph 1 software driving a CCD camera (SC1000 Orius, Gatan, Pleasanton, CA, USA) and saved as TIFF files. The brightness and contrast of the images were adjusted in Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA, USA).
Antibodies and western blotting
The aminopeptidase P1 antibody was previously described (Yoon et al. 2012) . The following antibodies were purchased commercially: FosB, p-CaMKII, ΔCaspase-3, Calpain-1, ERK, p-ERK, CREB, mTOR, p-mTOR, and Beclin1 (Cell Signaling Technology, Danvers, MA, USA); NeuN and MAP2 (Chemicon, Billerica, MA, USA) and -tubulin (Sigma-Aldrich).
For western blotting, mouse forebrains or hippocampi were homogenized in a homogenization buffer (320 mM sucrose, 10 mM Tris-HCl, 5 mM EDTA, pH 7.4) containing protease inhibitor cocktails (Sigma-Aldrich). The total protein concentrations of the homogenates were determined using the Bradford protein assay (Bio-Rad, Hercules, CA, USA). Proteins were dissolved and boiled for 5 min in an SDS sample loading buffer (pH 6.8) containing 50 mM Tris-HCl, 2% (w/v) SDS, 10% (v/v) glycerol, 12.5 mM EDTA, 0.02% (w/v) bromophenol blue and 5% (v/v) 2-mercaptoethanol. Samples containing 10 -12 μg of protein were loaded onto either 10% or 12% SDS-PAGE gels. For the western blot analysis of FosB/ΔFosB, proteins were separated on 4-20% gradient SDS-PAGE gels (Bio-Rad). The separated proteins were transferred to nitrocellulose membranes. After the protein transfers, membranes were cut into fragments, and the fragments were incubated in 5% skim milk for 30 min at room temperature. The membranes were incubated with primary antibodies overnight at 4 ∘ C or 1 h at room temperature, followed by 1 h incubations with horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA). After each step, the membranes were rinsed three times for 10 min with Tris-buffered saline (TBST, 0.1% Tween 20). The HRP signals were detected using the enhanced chemiluminescence (ECL) substrate (GE Healthcare, Little Chalfont, UK). All western blot experiments were independently repeated at least three times, and the resulting band intensities were quantified using MetaMorph NX 2.0 software (Molecular Devices, Sunnyvale, CA, USA).
Electroencephalogram recording
Ten-week-old mice were used for the EEG recordings. The EEG recording in freely moving mice was previously described (Kim et al. 2001) . Under avertin anesthesia (tribromoethanol, 20 mg/ml), four epidural electrodes were bilaterally implanted in the frontal and temporal regions with a reference electrode in the occipital region of the skull. After approximately 7-10 days of recovery, EEG signals and video recordings were simultaneously collected for 2 h. The EEG signals were amplified (Grass model 9 polygraph, Grass Technologies, West Warwick, RI, USA) and digitized at a sampling rate of 500 Hz (DigiData 1320A, Molecular Devices). The data were analyzed using custom macros written in Igor Pro 6 (WaveMetrics, Tigard, OR, USA).
Behavior analysis
All behavior experiments were carried out using male littermates. The data were analyzed using the videotracking software (Ethovision XT 8) from Noldus (Wageningen, The Netherlands). Behavioral assays were performed between 10:00 and 19:00, except for the home-cage activity measurement. To monitor home-cage activity, a specially designed transparent acrylic lid was mounted onto a standard mouse cage, and mouse activity was recorded with an infrared video recorder. Mice were housed individually and adapted to their modified home cages for 2 weeks before recording. The open-field activities were measured for 1 h in a white plastic chamber (40 × 40 × 40 cm) in a dimly lit room.
Novel-object recognition tests were performed as previously described (Kim et al. 2009 ). Briefly, mice were individually habituated in the open-field chamber (40 × 40 × 40 cm) for 1 h a day before the training session. Two novel objects were placed in the chamber during the training session, and one of the objects was replaced with a new one for the recall session. In each session, mice were allowed to explore the objects for 10 min. The interval between the training and the recall sessions was 24 h. A preference index was calculated by measuring the time spent exploring the new object over the total time spent exploring both the new and the familiar objects.
Elevated plus-maze tests were performed using a plus-shaped maze with two open arms and two closed arms surrounded by opaque walls. The maze was elevated 50 cm from the floor. During the test, each mouse was placed in the center of the maze, and the movement of the mouse was video recorded for 10 min. Entries into the open and closed arms, as well as time spent on these arms, were analyzed using video tracking software (Ethovision XT 8).
The training session for contextual and cued fear conditioning consisted of a 300-second exploration period [Pre-CS (conditioned stimulus), contextual], followed by presentation of an 18-second tone and a 2-second tone paired with a foot shock (0.7 mA) in the fear-conditioning chamber (Coulbourn Instruments, Whitehall, MI, USA). Afterward, each mouse was kept in the chamber for 60 seconds before being returned to its home cage. Contextual fear conditioning tests were performed in the same chamber (CS, contextual) after 24 h by monitoring mouse activity for 5 min. For cued fear conditioning, mice were placed in a distinct chamber located in a different room, and their activities (Pre-CS, cued) were monitored for 180 seconds, followed by presentation of a 180-second tone (CS, cued). The extent of activity suppression was indicated by the following ratio: (distance moved during Pre-CS − distance moved during CS)/(distance moved during Pre-CS).
For the Morris water maze assays, a white circular pool (110 cm in diameter) was filled with 23-25 ∘ C water. Two-day pre-training sessions consisted of one trial per day, and each mouse was allowed to remain on the visible platform (10 cm in diameter) for 30 seconds. During the hidden platform task, each mouse was trained with four trials per day, with inter-trial intervals of 1 min. In each trial, mice were released at one of three starting points in pseudo-random order (opposite quadrant, right adjacent quadrant, left adjacent quadrant and opposite quadrant) and allowed to find a submerged platform. If mice did not find the platform within 90 seconds, they were manually guided to the platform by the investigator. Mice were allowed to remain on the platform for 30 seconds before subsequent trials or before being returned to home cages. The probe test was performed 1 day after completion of the training sessions.
The accelerating rotarod (Ugo Basile, Gemonio, Italy) test was performed by training the mice once daily for 4 days. Mice were placed on motionless rods, which were then accelerated from 5 to 40 rpm over 5 min. The latencies to falling off the rotating rod were measured.
Statistical analysis
Statistical analyses were performed using Igor Pro 6 (WaveMetrics) and SPSS 17 (IBM, Armonk, NY, USA). The collected data were compared using two-tailed Student's t-tests. For multiple groups, analysis of variance (ANOVA) with Tukey's HSD post hoc test was used to compare samples. All bar graphs in the figures show the mean ± SEM.
Results
Aminopeptidase P1-mutant mice display behavioral hyperactivity
To investigate the behavioral consequence of aminopeptidase P1-deficiency, we first examined the home-cage activities of mice for three consecutive days (Fig. 1a, b) . Adult Xpnpep1 −/− mice (9-11 weeks old) displayed enhanced locomotor activities compared with the wild-type (WT) littermates (Fig. 1a) . Xpnpep1 −/− mice were more hyperactive during the light-off period (distance moved during 19:00-07:00; 213.8 ± 11.1% of WT; t (8) = −8.37, P < 0.001, Student's t-test) than during the light-on period (distance moved during 07:00-19:00 h; 127.2 ± 11.9% of WT; t (8) = −2.17, P > 0.05, Student's t-test) in their home cages. When we analyzed the total daily activity of the WT and Xpnpep1 −/− mice, there was a significant difference between the genotypes (t (8) = −8.11, P < 0.001, Student's t-test; Fig. 1b) . To further examine locomotor activity and exploratory behavior in a novel context, we monitored the activity of the Xpnpep1 −/− mice in open-field assays (Fig. 1c) . Xpnpep1 −/− mice were also hyperactive in the open-field box, indicating that Xpnpep1 −/− mice were hyperactive in both familiar and novel environments. Although the Xpnpep1 −/− mice moved more distance than the littermate controls during the 1-h open-field test ( Fig. 1d ; t (21) = −5.00, P < 0.001, Student's t-test), the degree of thigmotaxis (the tendency to remain close to the walls) was similar for both genotypes (t (21) = −0.70, P > 0.05), indicating that the anxiety levels were unaffected by the deficiency in aminopeptidase P1. Similarly, the Xpnpep1 −/− mice spent a normal amount of time on the open arms of the elevated plus-maze (Fig. 1e, f) . However, the Xpnpep1 −/− mice were still hyperactive in the elevated plus-maze and made significantly more entries onto each open and closed arm ( Fig. 1f ; t (14) = −4.46, P < 0.001). Collectively, these observations indicate that loss of aminopeptidase P1 activity in mice causes behavioral hyperactivity.
Deficiency in aminopeptidase P1 causes cognitive deficits
Individuals with IEM frequently exhibit intellectual disability (Kahler & Fahey 2003; Kolodny & Cable 1982; van Karnebeek & Stockler 2012) , and Xpnpep1 −/− mice exhibit microcephaly (Yoon et al. 2012) . We therefore examined whether cognitive impairments were accompanied by aminopeptidase P1 deficiency. The Xpnpep1 −/− mice exhibited impaired novel-object recognition memory (t (20) = 3.64, P < 0.01; Fig. 2a ). While WT mice preferred a new object in the novel-object recognition test, the Xpnpep1 −/− mice explored new and old objects equally. The Xpnpep1 −/− mice also displayed severe impairment in spatial learning and memory, as showed by The asterisks indicate significant differences between groups. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant (P ≥ 0.05); Student's t-test.
the Morris water maze (Fig. 2b-e) . The Xpnpep1 −/− mice failed to improve their learning performance during the 9-day training (t (12) = 1.49, P > 0.05), and a significant difference in escape latency [genotype × day interaction: (F 17,108 ) = 7.72, P < 0.001, two-way ANOVA with Tukey's HSD post hoc test] was observed between genotypes (Fig. 2b) . Consistent with these observations, the Xpnpep1 −/− mice spent an equal amount of time in each quadrant of the water maze pool during the probe trials [(F 3,24 ) = 2.4, P > 0.05, one-way ANOVA with Tukey's HSD post hoc test], whereas the WT mice spent significantly more time in the target quadrant than in the other quadrants [(F 3,24 ) = 42.5, P < 0.001; Fig. 2d, e] . The impaired performance of the Xpnpep1 −/− mice in the Morris water maze test unlikely originated from swimming or motor deficits because both genotypes showed no observable differences in swimming speed ( Fig. 2c ; t (12) = 0.17, P > 0.05). In addition, the Xpnpep1 −/− mice showed normal motor coordination and motor skill learning on the accelerating rotarod test (Fig. 2f) . Two-way repeated-measures ANOVA with Tukey's HSD post hoc analysis showed a significant effect of day [(F 3,39 ) = 9.48, P < 0.01] but not genotype [(F 1,12 ) = 3.11, P > 0.05] or genotype × day interaction [(F 7,84 ) = 0.23, P > 0.05] on latency.
We further examined the learning behaviors of the Xpnpep1 −/− mice with fear conditioning tests (Fig. 2g-i) . Because the absence of freezing behavior in Xpnpep1 −/− mice may stem from hyperactivity and impaired fear conditioning, we adopted suppression of activity as an index of an adaptive defense reaction in the fear conditioning test (Anagnostaras et al. 2000; Anagnostaras et al. 2003) . In contextual fear conditioning, which requires both the amygdala and hippocampus (Maren 2001; Phillips & LeDoux 1992) , a CS significantly suppressed the activity of the control mice (t (16) = 8.62, P < 0.001), whereas the activity of the mutant mice (t (12) = 1.51, P > 0.05) was not affected by the same CS (Fig. 2g) . In contrast, a CS significantly reduced the activities of both the control (t (16) = 4.3, P < 0.001) and Xpnpep1
−/− mice (t (12) = 5.49, P < 0.001) during the hippocampus-independent auditory-cued fear conditioning test (Fig. 2h) . The quantification of activity suppression suggests that aminopeptidase P1 deficiency in mice causes severe impairment in hippocampus-dependent learning and memory [ Fig. 2i; (F 3,28 ) = 19.57, P < 0.001].
Heterozygous Xpnpep1-mutant mice display normal locomotor activity and learning behavior
To determine the dosage sensitivity of aminopeptidase P1 in brain function, we first determined the expression levels of aminopeptidase P1 in the brains of heterozygous Xpnpep1-mutant (Xpnpep1 +/− ) mice. As shown in Fig. 3a , the aminopeptidase P1 levels in the Xpnpep1 +/− brain protein samples (10 μg) were lower than the levels in the WT control (i) Summary of activity suppression during the fear conditioning test. n = 9 (+/+) and 7 (−/−) mice. **P < 0.01; ***P < 0.001; n.s., not significant (P ≥ 0.05); Student's t-test (a-c, f-h) or one-way ANOVA with Tukey's HSD post hoc test (e, i).
samples. The heterozygous mutation led to a moderate reduction in aminopeptidase P1 in the brain [(F 2,12 ) = 368.9, P < 0.001; Fig. 3b ]. For quantification of the aminopeptidase P1 levels, we normalized the intensities of aminopeptidase P1 to those of -tubulin. The band intensities of -tubulin were linearly increased as the amount of protein increased (R = 0.98; Fig. 3c ).
We next examined the behaviors and cognitive functions of the Xpnpep1 +/− mice. In contrast to the homozygous Xpnpep1 mutant mice, the Xpnpep1 +/− mice (aged 8-10 weeks) did not exhibit behavioral hyperactivity. Locomotor habituation and exploratory behaviors of the Xpnpep1 +/− mice in the open-field box were not different from those of the WT mice ( Fig. 3d ; P > 0.05). The control and Xpnpep1 +/− mice traveled . n = 10 pairs. (g) The Xpnpep1 +/− mice display a normal novel-object recognition performance. Preference for a new object (left) and the total observation time (right) in the novel-object recognition test. n = 9 (+/+) and 8 (+/−) mice. (h-j) Normal fear conditioning in the Xpnpep1 +/− mice. Quantification of locomotor activity in the contextual (h) and cued (i) fear conditioning tests. Summary of activity suppression (j) during the fear conditioning test. n = 10 pairs. ***P < 0.001; n.s., not significant (P ≥ 0.05); Student's t-test. similar distances in the entire open-field box during the 1-h test ( Fig. 3e ; t (18) = −0.03, P > 0.05). The Xpnpep1 +/− mice also behaved normally in the elevated plus-maze (Fig. 3f ). There were no significant genotype differences in the time spent on the open arms (t (18) = −0.13, P > 0.05), number of entries onto the open and close arms (t (18) = −0.30, P > 0.05), and percent of entries onto the open arms (t (18) = 0.47, P > 0.05).
The heterozygous mutation of aminopeptidase P1 in mice also had no effect on learning and memory. Both the control and heterozygous mice showed a similar preference (t (15) = −0.35, P > 0.05) for the new object and spent similar amounts of time (t (15) = −0.19, P > 0.05) exploring the two objects (Fig. 3g) . In addition, presentation of the CS significantly reduced the locomotor activities of the control and Xpnpep1 +/− mice in both the contextual (+/+, t (18) = 9.07, P < 0.001; +/−, t (18) = 12.39, P < 0.001) and cued (+/+, t (18) = 7.09, P < 0.001; +/−, t (18) = 9.56, P < 0.001) fear conditioning tests (Fig. 3h, i) . We did not detect differences between the control and heterozygous genotypes regarding suppression of activity in either the contextual (t (18) = −0.58, P > 0.05) or cued (t (18) = −1.08, P > 0.05) fear conditioning tests, indicating intact learning and memory in the Xpnpep1 +/− mice (Fig. 3j) . Collectively, these results indicate that a single functional copy of the Xpnpep1 gene is sufficient for normal brain function and behavior.
Xpnpep1
−/− mice show epileptic EEG rhythms
Because epileptic seizures were observed in a patient with reduced aminopeptidase P activity (Blau et al. 1988) , we examined brain activity in conscious, freely moving mice using EEGs. Spontaneous epileptiform activities were detected in the brains of all Xpnpep1 −/− mice that we tested (n = 5, Fig. 4a ). The abnormal EEG rhythms in the Xpnpep1 −/− mice were observed throughout the entire forebrain. Epileptic discharges recorded in the Xpnpep1 −/− mice ranged from 5-12 Hz in spike frequency and from 0.3 to 6 seconds in duration. Interestingly, the spike frequency was inversely related to the duration of the discharges and to the number of spikes (Fig. 4b) . The higher-frequency discharges, comprised of a few spikes, exhibited shorter durations than the lower-frequency discharges. The inter-event intervals of the epileptic discharges ranged from 0.6 to 300 seconds in the Xpnpep1 −/− mice (Fig. 4c) . However, the observed epileptic discharges were not accompanied by episodes of ataxia or convulsion, indicating nonconvulsive epilepsy.
Loss of aminopeptidase P1 causes neurodegeneration in the hippocampal CA3 subfield
To investigate the neural mechanisms underlying the neurological and behavioral deficits in the Xpnpep1 −/− mice, we examined structural abnormalities in the brain. In addition to a reduced brain size (Yoon et al. 2012) , the Xpnpep1 −/− mice exhibited dispersion of neurons in the CA3 region of hippocampus (Fig. 5a, b) . Upon closer inspection, we observed a significant loss of neurons in the CA3 region of the hippocampus, but not in the dentate gyrus (DG) or CA1 regions, of 5-week-old Xpnpep1 −/− mice (Fig. 5c) . Consistent with this observation, the neuronal densities in the CA3 subfields of the Xpnpep1 −/− mice were significantly lower than those of the control mice (t (6) = 5.87, P < 0.01), as measured by staining for the neuronal marker NeuN (Fig. 5c, d ). In contrast, no significant genotype difference in the neuronal densities was observed in the DG (t (6) = 1.70, P > 0.05) and CA1 (t (6) = 1.14, P > 0.05) subfields of the hippocampus (Fig. 5d) .
The HE-stained brain sections from 5-week-old Xpnpep1 −/− mice exhibited a spongiform encephalopathy characterized by confluent vacuoles of varying sizes (5-40 μm) with dark surrounding neurons (Fig. 5e-h ), which may represent paraptosis-and autophagy-like neurodegeneration at an early age (Chow et al. 2007; Krantic et al. 2005; Okamoto et al. 1991; Whatley et al. 2008) . Intriguingly, these confluent vacuoles were mainly detected in the CA3 region of the 
Xpnpep1
−/− hippocampus (n = 4 mice, Fig. 5e-h ). The vacuoles were mostly clear and exhibited a foamy appearance due to clustering of numerous vacuoles (Fig. 5h) .
We further examined the ultrastructural pathology of the Xpnpep1 −/− CA3 neurons using electron microscopy ( Fig. 5i-n) . In contrast to the WT neurons (Fig. 5i) , many small vacuoles were detected in the soma and dendrites of apparently normal Xpnpep1 −/− CA3 neurons (Fig. 5j, k, m) , indicating an initial event that caused neurodegeneration of the Xpnpep1 −/− CA3 neurons. Small membrane-bound vacuoles were present in the CA3 neurons, and some vacuoles contained electron-dense materials (Fig. 5j, k, m ; yellow arrows). In addition, we observed numerous crater-like indentations in the large vacuoles of the Xpnpep1 −/− hippocampus ( Fig. 5l, n; asterisk) . These results indicate that metabolic dysfunction caused by aminopeptidase P1 deficiency leads to neuronal vacuolation and neurodegeneration in the selected subregion of the hippocampus.
We investigated whether haploinsufficiency of aminopeptidase P1 could cause the neurodegeneration and vacuolization that were observed in the hippocampi of the Xpnpep1 −/− mice. Consistent with the hippocampus-dependent learning and memory behaviors, these structural abnormalities were not detected in hippocampi of either 3-week-old (Fig. 6a,  c) or 5-week-old (Fig. 6b, d ) Xpnpep1 +/− mice (n = 3 littermate pairs). The WT and Xpnpep1 +/− mice exhibited similar neuronal densities in the DG (t (4) = −0.11, P > 0.05), CA3 (t (4) = −0.53, P > 0.05) and CA1 (t (4) = −0.22, P > 0.05) subfields of the hippocampus (Fig. 6e, f) . In addition, the body sizes (length, t (15) = −0.29, P > 0.05) and body weights (t (15) = −0.67, P > 0.05) of the 5-week-old Xpnpep1 +/− mice were not different from those of the WT mice ( Fig. 6g-i) . The brain sizes of the adult Xpnpep1 +/− mice also appeared normal (width, t (15) = −0.03, P > 0.05; length, t (15) = −0.18, P > 0.05; thickness, t (15) = −0.21, P > 0.05; Fig. 6j, k) . Collectively, adult Xpnpep1 +/− mice did not exhibit detectable growth retardation or hippocampal pathology.
Loss of aminopeptidase P1 activates cell death signaling in the hippocampus
To understand the altered signaling pathways associated with neurodegeneration in the Xpnpep1 −/− mice, we first determined the developmental expression patterns of aminopeptidase P1 in the brain. The expression levels of aminopeptidase P1 in the forebrain and hippocampus were consistently maintained throughout postnatal development (Fig. 7a, b) .
We next examined whether aminopeptidase P1 deficiency affected neuronal activity in the Xpnpep1 −/− hippocampus. Indeed, the expression level of ΔFosB, a truncated variant of FosB that is accumulated in repeatedly activated neurons (Cruz et al. 2013) , was markedly increased in the Xpnpep1 −/− hippocampus (t (6) = −5.36, P < 0.01), indicating enhanced neuronal activity in the Xpnpep1 −/− neurons (Fig. 7c, d ). In addition, we found that phosphorylated Ca 2+ /calmodulin-dependent protein kinase II beta (p-CaMKII ; t (6) = −3.44, P < 0.05), cleaved Caspase-3 (ΔCaspase-3; 17 kDa, t (6) = −2.95, P < 0.05; 19 kDa, t (6) = −3.17, P < 0.05), Calpain-1 (75 kDa, t (6) = −3.34, P < 0.05), and LC3B (I, t (6) = −10.4, P < 0.001; II, t (6) = −5.3, P < 0.01) were upregulated in the Xpnpep1 −/− hippocampus (Fig. 7c) . Because these signaling proteins are associated with common types of cell death including necrosis, apoptosis, and autophagy, upregulation of these signaling proteins reflects neurodegeneration in the Xpnpep1 −/− hippocampus (Yuan et al. 2003) . Notably, punctate Calpain-1 and LC3B signals were mainly detected around the large vacuoles (Fig. 7d) . Therefore, aminopeptidase P1 deficiency, in which neurodegeneration occurs during the early developmental stages, shares a number of neurodegenerative signaling pathways with the etiology of late-onset neurodegenerative disorders (Gorman 2008) .
Discussion
This study shows that loss of aminopeptidase P1 leads to severe behavioral and neurological deficits in mice. Homozygous Xpnpep1-mutant mice exhibit hyperactivity and severely impaired learning with epileptic EEG rhythms. These behavioral and neurological complications are associated with neurodegeneration and neuronal vacuolation in the hippocampal CA3 regions. The complex behavioral deficits observed in the Xpnpep1 −/− mice suggest that various neuropsychiatric disorders can arise from metabolic dysfunction in the brain without the presence of mutations in ion channels or synaptic genes. To date, most studies involved in neurological and psychiatric disorders have focused on genes encoding neuronal ion channels, neurotransmitter receptors and synaptic proteins (Cooper & Jan 1999; Imbrici et al. 2013; van Spronsen & Hoogenraad 2010; Volk et al. 2015; Zoghbi & Bear 2012) . Our findings may help to extend the current understanding of the origin of developmental psychiatric disorders and neurological symptoms in a variety of IEMs.
The behavioral and cognitive consequences of aminopeptidase P1 deficiency in humans are unknown. Our results predict enhanced susceptibility of humans with aminopeptidase P1 deficiency to hyperactivity disorder and intellectual disability. Disruption of aminopeptidase P1 in mice caused abnormally enhanced locomotor activities (Fig. 1) and severe impairments in hippocampus-dependent learning and memory (Fig. 2) . Adult Xpnpep1 −/− mice display impaired performance in novel-object recognition, the Morris water maze task, and contextual fear conditioning. Notably, the escape latencies of the Xpnpep1 −/− mice measured on day 1 (4 trials) of water maze training were significantly different from those of the control mice. This result suggests that other issues, such as attention deficits or lack of motivation to find the platform, may affect the water-maze performance of Xpnpep1 −/− mice. Indeed, distractibility is usually comorbid with excessive activity in human patients with attention-deficit hyperactivity disorder. It is possible that reduced attention during the pre-training acclimation sessions or training sessions might affect the water-maze performance of Xpnpep1 −/− mice. However, considering that the Xpnpep1 −/− mice exhibit normal activity suppression in cued fear conditioning, the impaired hippocampus-dependent memory function seems attributable mainly to cognitive deficits in the Xpnpep1 −/− mice. Similarly, the impaired performance of the Xpnpep1 −/− mice in the cognitive behavioral task is unlikely to be associated with reduced motivation. During the training trials of the water maze test, the Xpnpep1 −/− mice were continually swimming without exhibiting floating behaviors, and they were easily guided to the platform by the investigator when the mice failed to find the hidden platform within allotted time. After reaching the platform, the Xpnpep1 −/− mice climbed onto the platform and spent the allotted time there. In addition, the WT and Xpnpep1 −/− mice spent similar amounts of time exploring objects in the novel-object recognition test. Severe hippocampal pathologies further support impaired hippocampus-dependent learning and memory in Xpnpep1 −/− mice. In contrast to the Xpnpep1 −/− mice, the Xpnpep1 heterozygous mutant mice do not display any clear behavioral abnormalities. These observations exclude the dosage sensitivity of aminopeptidase P1 in the development of neuropsychiatric disorders. Thus, almost complete loss of aminopeptidase P1 activity causes the behavioral disorders and intellectual disability. However, it is worth emphasizing that the gene mutations that are responsible for IEMs do not produce uniform neurological phenotypes in humans, as opposed to mutations of the same gene in mice. All IEM patients, as the name of the disease implies, exhibit biochemical abnormalities, but neurological complications are frequently, but not always, observed in the patients (Garcia-Cazorla et al. 2009 ). For instance, patients with homocystinuria have broad intelligence quotient scores ranging from 10 to 135, and approximately one third of patients do not have an intellectual disability (Moog et al. 2008) . Similarly, the majority, but not all, of patients with untreated phenylketonuria have an intellectual disability, but epilepsy is observed in 28% of the patients (Murphy et al. 2008) . There is a possibility that the distinct absolute activity of the defective enzyme produces different phenotypes in patients with metabolic disease. Aminopeptidase P1 deficiency also seems to exhibit heterogeneous symptoms; microcephaly and epilepsy have been observed in one of two brothers with peptiduria (Blau et al. 1988) . However, the consequences of aminopeptidase P1 deficiency in humans remain to be investigated in various domains of behavior and cognition.
Compared with other IEMs, aminopeptidase P1 deficiency is extremely rare in humans. Aminopeptidase P1 may be important for survival, and a complete lack of its enzymatic activity can be fatal to humans. Indeed, infants born with metabolic diseases frequently die without identification of the defective enzyme, and thus, the incidence of most IEMs is often underestimated. In our observations, the Xpnpep1 −/− pups in an inbred C57BL/6J background barely survived due to perinatal or juvenile lethality, but the Xpnpep1 −/− pups in a hybrid background that was derived from intercrosses between C57BL/6J and 129S4/SvJae heterozygous parents were viable with modest postnatal lethality (Yoon et al. 2012) . Although the surviving adult Xpnpep1 −/− mice displayed cognitive and neurological deficits, the Xpnpep1 −/− mice that were older than 4 weeks of age did not show adult lethality. These findings suggest that a lack of aminopeptidase P1 activity may be more severe during infancy than childhood. In accordance with this finding, human patients with aminopeptidase P1 deficiency exhibit an age-dependent decrease in the urinary excretion of undigested imino-oligopeptides (Blau et al. 1988) .
In aminopeptidase P1 deficiency, the harmful metabolites, perhaps including undigested imino-oligopeptides, that cause neurodevelopmental disorders are unknown, but they seem to originate from endogenous sources because exogenously loaded peptides with penultimate proline residues have no effect on the levels of excreted imino-oligopeptides in the human patient (Blau et al. 1988) . In mammals, tens of bioactive peptides, such as cytokines and neuropeptides, contain a proline residue in the penultimate N-terminal position, and X-Pro motifs can be generated from the proteolytic degradation of proteins through the actions of other proteases or peptidases (Vanhoof et al. 1995) . Our study suggests that accumulation of these undigested imino-oligopeptides can give rise to neurodegeneration in the brain. Neuronal loss and vacuolation were observed in the hippocampal CA3 subfields of the Xpnpep1 −/− mice but not in other brain regions. These prominent features of neurodegeneration were accompanied by activation of multiple cell death pathways (Gorman 2008; Yuan et al. 2003) . The vacuolation and loss of hippocampal CA3 neurons observed in the Xpnpep1 −/− mice were similar to epilepsy-induced pathological changes previously observed in rodents (Ribak & Baram 1996; Tohyama et al. 2000; Zhou et al. 2005) . The epileptic EEG rhythms in the Xpnpep1 −/− mice suggest that hippocampal disorganization is associated with epilepsy and that the deficiency in aminopeptidase P1 affects neuronal activity. It is conceivable that frequent and large spontaneous excitatory synaptic transmissions at mossy fiber-CA3 synapses and associational/commissural-CA3 synapses might result in selective excitotoxic cell death of CA3 neurons in the Xpnpep1 −/− brain (Henze et al. 2002; Traub & Miles 1991) .
Collectively, this study provides experimental evidence that deficiency in aminopeptidase P1 leads to behavioral, cognitive and neurological deficits in mice. Thus, aminopeptidase P1-dependent peptide metabolism is critical for normal brain function.
